A generic competitor to the EpiPen won’t cost any less than the version already on the market, despite the Trump administration touting it as a cheaper alternative.

Teva Pharmaceuticals on Tuesday said its drug is now available in limited quantities in the United States, for a wholesale cost of $300. The drug already on the market from original manufacturer Mylan also costs $300.

The Food and Drug Administration (FDA) approved generic versions of both the EpiPen and the lower dose EpiPen Jr. in August. FDA Commissioner Scott Gottlieb touted the approvals as part of an “overarching effort to remove barriers” to access to “critically important” drugs.

Read more at The Hill.